Safer handling of antineoplastic drugs in Australian pharmacies

Occupational exposure to antineoplastic drugs is usually a series of small contacts rather than one visible event. These powerful cancer treatments can damage DNA, and pharmacy workers may encounter powders, solutions, tablets, vials, packaging, contaminated surfaces, waste or spills. Repeated low-level exposure can cause dermatitis and may increase long-term risks, including reproductive harm and cancer.

Australian pharmacy settings range from public hospitals and private day-treatment units in Sydney and Melbourne to regional hospitals, specialist compounding pharmacies and community pharmacies dispensing oral anticancer medicines. Each setting has different workflows, staffing and delivery arrangements, yet all need the same principle: prevent contamination at the source, support workers who report concerns, and keep exposure controls consistent through cleaning, waste and emergency response.

Why pharmacy work needs a dedicated approach

Exposure prevention works best as a system rather than a pile of personal protective equipment. A safe system identifies hazardous medicines, separates clean and contaminated work, maintains equipment, trains several job roles and checks whether controls remain effective. This approach matches the preventive, worker-consultation model used in EU-OSHA guidance and can be adapted through OSHwiki resources and OiRA-style risk questions.

Many antineoplastics are cytotoxic, mutagenic, carcinogenic or reproductive toxins, while others pose a narrower set of hazards. Skin contact with residues is a frequent route of exposure; inhalation of aerosols or droplets and hand-to-mouth transfer are also possible. Acute effects can include irritation, headache and nausea, while the more serious concern is sensitisation and long-term health damage. The evidence for some outcomes remains developing, so precautionary controls are justified.

The label hazardous drug can help organise controls, but it should not become a narrow legal list. Hazardous-drug programs often cover medicines beyond cancer treatment, and each product’s safety data sheet, manufacturer’s instructions and clinical formulation must still guide handling. A worker can be exposed outside the compounding room: while opening a delivery, counting stock, cleaning a bench, handling waste or supporting a colleague during an emergency.

Exposure pathways across the medicine pathway

Trace the exposure from receiving to disposal. Risk points include opening shipping cartons, checking stock, moving vials between storerooms and fridges, preparing doses, drawing up injections, transferring medicines into infusion equipment, packing patient supplies and returning unused products. Tasks may be brief but frequent, and interruptions increase the chance that gloves, labels or closed-transfer devices are omitted.

Surface contamination can persist after a task appears finished. A clean-looking bench, keyboard, door handle or waste lid may carry trace residues that transfer to hands. Spills, leaking vials, incompatible cleaning methods and poorly closed waste containers can turn routine work into higher exposure. Sharps add a distinct injury route and can carry medicine directly into the bloodstream.

Large metropolitan hospitals may run busy oncology units with dedicated technicians, while smaller regional services receive stock by courier or share staff across wards. Private infusion centres and compounding pharmacies add another layer of contractors, cleaners and transport workers. Risk assessment should map who enters each area, what they carry and which tasks are performed outside controlled spaces.

Legal duties and risk assessment

Employers operate under the Safe Work Australia model laws as enacted by each state and territory. Examples include New South Wales’ Work Health and Safety Act 2010, Queensland’s Work Health and Safety Act 2011 and Victoria’s Occupational Health and Safety Act 2004. Corresponding hazardous substances regulations, GHS classifications and emergency rules impose jurisdiction-specific duties, while Safe Work Australia codes guide implementation and become enforceable when adopted by law or contract. The duty to provide safe systems, information, training, facilities and supervision applies alongside duties for workers and others.

A pharmacy risk assessment should cover the whole drug pathway and be reviewed when a product, device, room, process or supplier changes. It should identify who may be exposed, consider less hazardous options where clinically acceptable, apply the control hierarchy, specify clean-up and waste methods, and record emergency contacts. Therapeutic goods are regulated by the TGA under the Therapeutic Goods Act 1985, while state pharmacy boards govern registration and professional practice. A substance may have no numerical exposure limit and still require strong controls. Workers’ compensation and clinical follow-up routes should be confirmed before an incident occurs.

Risk registers should capture near misses, spills and changing work patterns, not only confirmed illness. Public-health work on ambulance call record mining has used free-text analysis to detect clusters of headache-related calls earlier. The transferable lesson for pharmacies is to use consistent reporting and review patterns without exposing personal health information; a headache-detection algorithm should never be imported into occupational decisions.

Controls that reduce exposure at source

Use the control hierarchy. Eliminate or reduce the open handling of hazardous medicines where clinically safe: use sealed, manufacturer-approved containers; compatible closed-system transfer devices; prefilled or ready-to-administer products; centralised preparation; and validated automated compounding where suitable. Outsourcing can reduce exposure in dispensing pharmacies, but the contract must define transport, packaging, labelling, incident reporting and responsibilities.

Contain any remaining hazard at source. Compounding should occur in a purpose-designed external-window cabinet with appropriate HEPA filtration and facility-specific exhaust; an ordinary laboratory fume hood or clean bench is not automatically suitable. Cabinets require installation, qualification, planned maintenance and cleaning. Facility design should support clean-to-dirty movement, segregated storage, adequate space for gowning and controlled access by trained staff.

Work practices form the next layer. Restrict access, keep stock and waste labelled, use compatible transfer methods, wear chemically appropriate gloves with protective clothing and eye protection, and remove contaminated items before touching phones, paperwork or communal equipment. Gloves do not replace hand hygiene, and they must be changed according to the task, product and procedure. No eating, drinking, applying cosmetics or storing personal items should occur in compounding or waste areas.

Prepare for spills before they happen. Isolate the area, use a trained spill-response procedure and the facility’s spill kit, and follow the product safety data sheet for decontamination and personal response. Do not dry-sweep residues or pour them into ordinary sinks. Place contaminated sharps, items and linen in approved cytotoxic-waste streams. Maintain eyewash or emergency flushing access and tell managers and occupational health providers promptly after suspected exposure.

Training, monitoring and worker participation

Training should be role-specific, practical and repeated, because rules change and routines drift. A European adult-learning resource collecting practical training themes illustrates the value of linking course content to real tasks, decisions and workplace problems. Induction should cover cleaners, couriers, technicians, nurses and relief staff as well as pharmacists, with refresher sessions after equipment, products or procedures change.

The core syllabus should include practical demonstration of the following:

A simple review can track several useful indicators:

Monitoring is most useful when it leads to action, not blame. Workers should be consulted about symptoms, workarounds and barriers to reporting, and confidential occupational-health arrangements should support skin checks or other surveillance when the risk assessment indicates a need. Reproductive-health advice should be available without forcing affected workers to disclose personal details. Managers should feed findings back to the team and adjust work before an incident requires enforcement.

Make safe handling an everyday practice

Safe handling becomes durable when it is built into quality and procurement rather than treated as an emergency response. Pharmacy leaders can set measurable expectations for source control, equipment maintenance, competency, waste segregation and incident follow-up. Workers should see the same standard in public and private services, including after hours and during stock shortages.

Start this week by nominating a responsible lead and reviewing the end-to-end pathway for each antineoplastic product handled locally. Check the current risk assessment against the latest safety data sheets, confirm that spill and waste materials are available, and schedule hands-on training for everyone who enters controlled areas. Record the findings, assign owners and dates, and revisit the pathway after the next supplier, product or workflow change.

Make each dose a reason to confirm the system works: the medicine is identified, the transfer is closed where possible, the workspace is clean, the waste route is understood and the worker knows how to report a problem. Consistent action across every shift turns safe handling from individual caution into an everyday pharmacy practice.